<DOC>
	<DOC>NCT00129818</DOC>
	<brief_summary>The study is designed to assess the efficacy and safety of famciclovir 250 mg twice a day (bid) suppressive treatment in men and women with herpes virus type 2 (HSV-2) infection, with and without a reported history of genital herpes and with or without herpes virus type 1 (HSV-1) seropositivity.</brief_summary>
	<brief_title>A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding</brief_title>
	<detailed_description />
	<mesh_term>Herpes Genitalis</mesh_term>
	<mesh_term>Famciclovir</mesh_term>
	<mesh_term>2-Aminopurine</mesh_term>
	<criteria>Males or nonpregnant females at least 18 years of age with HSV2 seropositive serology with or without history of clinically diagnosed recurrent genital herpes Pregnancy History of renal dysfunction Use of immunosuppressive therapy, including steroids (other than topical or inhaled), or use of probenecid Hypersensitivity to famciclovir, valacyclovir or drugs with similar chemical structure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Genital herpes</keyword>
	<keyword>viral shedding</keyword>
	<keyword>famciclovir</keyword>
	<keyword>Symptomatic genital herpes</keyword>
	<keyword>Asymptomatic genital herpes</keyword>
</DOC>